Cullinan Therapeutics Inc [CGEM] stock is trading at $8.65, down -0.40%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CGEM shares have gain 9.57% over the last week, with a monthly amount glided 4.41%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cullinan Therapeutics Inc [NASDAQ: CGEM] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $30. Previously, Stifel started tracking the stock with Buy rating on May 01, 2024, and set its price target to $40. On April 15, 2024, William Blair initiated with a Outperform rating. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $30 on February 15, 2024. TD Cowen initiated its recommendation with a Outperform. BTIG Research started tracking with a Buy rating for this stock on November 21, 2022, and assigned it a price target of $20. In a note dated April 27, 2021, Morgan Stanley upgraded an Overweight rating on this stock but restated the target price of $40.
Cullinan Therapeutics Inc [CGEM] stock has fluctuated between $6.85 and $24.76 over the past year. Currently, Wall Street analysts expect the stock to reach $31.5 within the next 12 months. Cullinan Therapeutics Inc [NASDAQ: CGEM] shares were valued at $8.65 at the most recent close of the market. An investor can expect a potential return of 264.16% based on the average CGEM price forecast.
Analyzing the CGEM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.29 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.33 points at the first support level, and at 8.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.91, and for the 2nd resistance point, it is at 9.17.
Ratios To Look Out For
For context, Cullinan Therapeutics Inc’s Current Ratio is 11.62. In addition, the Quick Ratio stands at 11.62 and the Cash Ratio stands at 2.8.
Transactions by insiders
Recent insider trading involved Jones Jeffrey Alan, Chief Medical Officer, that happened on Feb 25 ’25 when 4895.0 shares were sold. President and CEO, AHMED NADIM completed a deal on Feb 25 ’25 to sell 12529.0 shares. Meanwhile, Chief Scientific Officer Michaelson Jennifer sold 3756.0 shares on Feb 25 ’25.
